Repurposing therapies for the personalised treatment of cystic fibrosis

References

• Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45:1160–1167.
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M. CFTR Modulators: Shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016;7:275.
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073.
   PubMed Web of Science ®Google Scholar
• Riordan JR. Assembly of functional CFTR chloride channels. Annu Rev Physiol. 2005;67:701–718.
   PubMed Web of Science ®Google Scholar
• Linsdell P. Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp Physiol. 2006;91:123–129.
   PubMed Web of Science ®Google Scholar
• Tang L, Fatehi M, Linsdell P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J Cyst Fibros. 2009;8:115–121.
   PubMed Web of Science ®Google Scholar
• Spielberg DR, Clancy JP. Cystic fibrosis and its management through established and emerging therapies. Annu Rev Genomics Hum Genet. 2016;17:155–175.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689.
   PubMed Web of Science ®Google Scholar
• Tang XX, Ostedgaard LS, Hoegger MJ, et al. Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J Clin Invest. 2016;126:879–891.
   PubMed Web of Science ®Google Scholar
• Yuan S, Hollinger M, Lachowicz-Scroggins ME, et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med. 2015;7:276ra27.
   PubMed Web of Science ®Google Scholar
• Shah VS, Ernst S, Tang XX, et al. Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies. Proc Natl Acad Sci U S A. 2016;113:5382–5387.
   PubMed Web of Science ®Google Scholar
• Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med. 2015;372:351–362.
   PubMed Web of Science ®Google Scholar
• Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16:45–56.
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med. 2012;18:81–91.
   PubMed Web of Science ®Google Scholar
• Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A. 2008;105:3256–3261.
   PubMed Web of Science ®Google Scholar
• Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell. 2012;148:164–174.
   PubMed Web of Science ®Google Scholar
• Okiyoneda T, Barrière H, Bagdány M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010;329:805–810.
   PubMed Web of Science ®Google Scholar
• Veit G, Avramescu RG, Chiang AN, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27:424–433.
   PubMed Web of Science ®Google Scholar
• Wiencek JR, Lo SF. Advances in the diagnosis and management of cystic fibrosis in the genomic era. Clin Chem. 2018. DOI:10.1373/clinchem.2017.274670.
   PubMedGoogle Scholar
• Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13:29–36.
   PubMed Web of Science ®Google Scholar
• Quon BS, Wilcox PG. A new era of personalized medicine for cystic fibrosis - at last! . Can Respir J. 2015;22:257–260.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106:18825–18830.
   PubMed Web of Science ®Google Scholar
• Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009;8:153–171.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med. 2013;3. doi:10.1101/cshperspect.a009761.
   PubMed Web of Science ®Google Scholar
• Kalid O, Mense M, Fischman S, et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des. 2010;24:971–991.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1117–30.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108:18843–18848.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672.
   PubMed Web of Science ®Google Scholar
• De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13:674–680.
   PubMed Web of Science ®Google Scholar
• Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013;110:4404–4409.
   PubMed Web of Science ®Google Scholar
• Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008;105:2064–2069.
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372:719–727.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;182:1262–1272.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38:59–69.
   PubMed Web of Science ®Google Scholar
• Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2:539–547.
   PubMed Web of Science ®Google Scholar
• Zainal Abidin N, Haq IJ, Gardner AI, et al. Ataluren in cystic fibrosis: development, clinical studies and where are we now? Expert Opin Pharmacother. 2017;18:1363–1371.
   PubMed Web of Science ®Google Scholar
• Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat. 2002;19:575–606.
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2:527–538.
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373:1783–1784.
   PubMed Web of Science ®Google Scholar
• Ren CL, Morgan RL, Oermann C. Cystic fibrosis foundation pulmonary guidelines: use of CFTR modulator therapy in patients with cystic fibrosis. Ann Am Thorac Soc. 2018. DOI:10.1513/AnnalsATS.201707-539OT.
   PubMed Web of Science ®Google Scholar
• Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6:246ra296.
   Web of Science ®Google Scholar
• Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med. 2014;6:246ra297.
   Web of Science ®Google Scholar
• Phuan PW, Veit G, Tan J, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014;86:42–51.
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al. VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219–1225.
   PubMed Web of Science ®Google Scholar
• Davies JC, Cunningham S, Harris WT, et al.; KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4:107–115.
   PubMed Web of Science ®Google Scholar
• Moss RB, Flume PA, Elborn JS, et al.; VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3:524–533.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Hug C, Marigowda G, et al.; VX14-809-109 investigator group. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5:557–567.
   PubMed Web of Science ®Google Scholar
• Rowe SM, McColley SA, Rietschel E, et al.; VX09-809-102 Study Group. Lumacaftor/Ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann Am Thorac Soc. 2017;14:213–219.
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377:2013–2023.
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Pilewski JM, Griese M, et al.; VX11-661-101 Study Group Tezacaftor/Ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med. 2018;197:214–224.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377:2024–2035.
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Solomon GM, Zeitlin PL, et al. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017;16:371–379.
   PubMed Web of Science ®Google Scholar
• Balfour-Lynn IM. Personalised medicine in cystic fibrosis is unaffordable. Paediatr Respir Rev. 2014;15(S1):2–5.
   PubMedGoogle Scholar
• Elborn JS. Personalised medicine for cystic fibrosis: treating the basic defect. Eur Respir Rev. 2013;22:3–5.
   PubMedGoogle Scholar
• Harutyunyan M, Huang Y, Mun KS, et al. Personalized medicine in CF: from modulator development to therapy for cystic fibrosispatients with rare CFTR mutations. Am J Physiol Lung Cell Mol Physiol. 2017. published online Dec 14. doi:10.1152/ajplung.00465.2017.
   PubMed Web of Science ®Google Scholar
• Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189–1195.
   PubMed Web of Science ®Google Scholar
• Shchors K, Massaras A, Hanahan D. Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell. 2015;28:456–471.
   PubMed Web of Science ®Google Scholar
• Schmidt BZ, Haaf JB, Leal T, et al. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. Clin Pharmacol. 2016;8:127–140.
   PubMedGoogle Scholar
• Dey I, Shah K, Bradbury NA. Natural compounds as therapeutic agents in the treatment cystic fibrosis. J Genet Syndr Gene Ther. 2016;7.
   PubMedGoogle Scholar
• Woodworth BA. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency. Laryngoscope. 2015;125(S7):S1–S13.
   PubMedGoogle Scholar
• Zhang Y, Yu B, Sui Y, et al. Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from chinese medicinal plants. PLoS One. 2014;9:e94302.
   PubMed Web of Science ®Google Scholar
• Zhang S, Blount AC, McNicholas CM, et al. Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probability. PLoS One. 2013;8:e81589.
   PubMed Web of Science ®Google Scholar
• Dhooghe B, Bouckaert C, Capron A, et al. Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice. Biol Open. 2015;4:929–936.
   PubMed Web of Science ®Google Scholar
• Mutyam V, Du M, Xue X. Discovery of clinically approved agents that promote suppression of cftr nonsense mutations. Am J Respir Crit Care Med. 2016;194:1092–1103.
   PubMed Web of Science ®Google Scholar
• Leier G, Bangel-Ruland N, Sobczak K, et al. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem. 2012;29:775–790.
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Wiley C, Felton LAS, et al. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015;14:228–236.
   PubMed Web of Science ®Google Scholar
• Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med. 2008;177:506–515.
   PubMed Web of Science ®Google Scholar
• Leonard A, Lebecque P, Dingemanse J, et al. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros. 2012;11:231–236.
   PubMed Web of Science ®Google Scholar
• Carlile GW, Robert R, Goepp J, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros. 2015;14:16–25.
   PubMed Web of Science ®Google Scholar
• Maiuri L, Raia V, Kroemer G. Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ. 2017;24:1825–1844.
   PubMed Web of Science ®Google Scholar
• Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600–602.
   PubMed Web of Science ®Google Scholar
• Egan ME, Glöckner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of DeltaF508-CFTR protein in cystic fibrosis epithelial cells. Nat Med. 2002;8:485–492.
   PubMed Web of Science ®Google Scholar
• Mall M, Kunzelmann K. Correction of the CF defect by curcumin: hypes and disappointments. Bioessays. 2005;27:9–13.
   PubMed Web of Science ®Google Scholar
• Norez C, Vandebrouck C, Bertrand J, et al. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br J Pharmacol. 2014;171:4831–4849.
   PubMed Web of Science ®Google Scholar
• Meijer L, Nelson DJ, Riazanski V, et al. Modulating innate and adaptive immunity by (r)-roscovitine: potential therapeutic opportunity in cystic fibrosis. J Innate Immun. 2016;8:330–349.
   PubMed Web of Science ®Google Scholar
• Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010;6:25–33.
   PubMed Web of Science ®Google Scholar
• Weinreich F, Wood PG, Riordan JR, et al. Direct action of genistein on CFTR. Pflugers Arch. 1997;434:484–491.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Hughes LK, Cai Z, et al. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol. 2008;153:1311–1323.
   PubMed Web of Science ®Google Scholar
• Lim M, McKenzie K, Floyd AD, et al. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004;31:351–357.
   PubMed Web of Science ®Google Scholar
• Arora K, Yarlagadda S, Zhang W, et al. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation. Am J Physiol Lung Cell Mol Physiol. 2016;311:L364–74.
   PubMed Web of Science ®Google Scholar
• Rayyan E, Polito S, Leung L, et al. Effect of genistein on basal jejunal chloride secretion in R117H CF mice is sex and route specific. Clin Exp Gastroenterol. 2015;8:77–87.
   PubMed Web of Science ®Google Scholar
• Costabile G, d’Angelo I, Rampioni G, et al. Toward repositioning niclosamide for antivirulence therapy of pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology. Mol Pharm. 2015;12:2604–2617.
   PubMedGoogle Scholar
• Abou Alaiwa MH, Launspach JL, Sheets KA, et al. Repurposing tromethamine as inhaled therapy to treat CF airway disease. JCI Insight. 2016;1:e87535.
   PubMed Web of Science ®Google Scholar
• Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibros. 2011;10:1–8.
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al.; B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144:215–305.
   PubMed Web of Science ®Google Scholar
• De Boeck K, Haarman E, J H, et al.; DPM-CF-204 Study Group. Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. J Cyst Fibros. 2017;16:380–387.
   PubMed Web of Science ®Google Scholar
• Costabile G, d’Angelo I, d’Emmanuele Di Villa Bianca R, et al. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections. J Control Release. 2016;238:80–91.
   PubMed Web of Science ®Google Scholar
• Stolarz AJ, Farris RA, Wiley CA, et al. Fenofibrate attenuates neutrophilic inflammation in airway epithelia: potential drug repurposing for cystic fibrosis. Clin Transl Sci. 2015;8:696–701.
   PubMed Web of Science ®Google Scholar
• Charrier C, Rodger C, Robertson J, et al. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet J Rare Dis. 2014;9:189.
   PubMed Web of Science ®Google Scholar
• Devereux G, Fraser-Pitt D, Robertson J, et al. Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum. EBioMedicine. 2015;2:1507–1512.
   PubMed Web of Science ®Google Scholar
• Devereux G, Steele S, Griffiths K, et al. An open-label investigation of the pharmacokinetics and tolerability of oral cysteamine in adults with cystic fibrosis. Clin Drug Investig. 2016;36:605–612.
   PubMed Web of Science ®Google Scholar
• Fraser-Pitt D, Mercer D, Lovie E, et al. Activity of cysteamine against the cystic fibrosis pathogen burkholderia cepacia complex. Antimicrob Agents Chemother. 2016;60:6200–6206.
   PubMed Web of Science ®Google Scholar
• Mijnders M, Kleizen B, Correcting BI. CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Current Opinion in Pharmacology. 2017;34:83–90.
   PubMed Web of Science ®Google Scholar
• Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014;10:654–663.
   PubMed Web of Science ®Google Scholar
• Balch WE, Roth DM, HuttD M. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol. 2011;3. doi:10.1101/cshperspect.a004499.
   PubMed Web of Science ®Google Scholar
• Pankow S, Bamberger C, Calzolari D, et al. F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature. 2015;528:510–516.
   PubMed Web of Science ®Google Scholar
• Amaral MD, Balch WE. Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros. 2015;14:687–699.
   PubMed Web of Science ®Google Scholar
• Villella VR, Esposito S, Bruscia EM, et al. Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. Cell Death Differ. 2013;20:1101–1115.
   PubMed Web of Science ®Google Scholar
• Maiuri L, Luciani A, Giardino I, et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol. 2008;180:7697–7705.
   PubMed Web of Science ®Google Scholar
• Luciani A, Villella VR, Vasaturo A, et al. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol. 2009;183:2775–2784.
   PubMed Web of Science ®Google Scholar
• Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol. 2010;12:863–875.
   PubMed Web of Science ®Google Scholar
• Luciani A, Villella VR, Esposito S, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 cystic fibrosis transmembrane conductance regulator. Autophagy. 2012;8:1657–1672.
   PubMed Web of Science ®Google Scholar
• Villella VR, Esposito S, Bruscia EM, et al. Targeting the intracellular environment in cystic fibrosis: restoring autophagy as a novel strategy to circumvent the CFTR defect. Front Pharmacol. 2013;4:1.
   PubMed Web of Science ®Google Scholar
• Abdulrahman BA, Khweek AA, Akhter A, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by burkholderia cenocepacia in a model of cystic fibrosis. Autophagy. 2011;7:1359–1370.
   PubMed Web of Science ®Google Scholar
• Junkins RD, McCormick C, Lin TJ. The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections. Autophagy. 2014;10:538–547.
   PubMed Web of Science ®Google Scholar
• Mayer ML, Blohmke CJ, Falsafi R, et al. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J Immunol. 2013;190:1227–1238.
   PubMed Web of Science ®Google Scholar
• Zhang S, Stoll G, Pedro JMBS, et al. Evaluation of autophagy inducers in epithelial cells carrying the F508del mutation of the cystic fibrosis transmembrane conductance regulator CFTR. Cell Death Dis. 2018;9:191.
   PubMed Web of Science ®Google Scholar
• Farinha CM, Matos P, Amaral MD. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. Febs J. 2013;280:4396–4406.
   PubMed Web of Science ®Google Scholar
• Farinha CM, King-Underwood J, Sousa M, et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol. 2013;20:943–955.
   PubMed Web of Science ®Google Scholar
• Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;63:827–834.
   PubMed Web of Science ®Google Scholar
• Jensen TJ, Loo MA, Pind S, et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell. 1995;83:129–135.
   PubMed Web of Science ®Google Scholar
• Farinha CM, Swiatecka-Urban A, Brautigan DL, et al. Regulatory crosstalk by protein kinases on CFTR trafficking and activity. Front Chem. 2016;4:1.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tosco A, Villella VR, et al. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol Cell Pediatr. 2016;3:13.
   PubMedGoogle Scholar
• Nurminskaya MV, Belkin AM. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol. 2012;294:1–97.
   PubMed Web of Science ®Google Scholar
• D’Eletto M, Farrace MG, Rossin F, et al. Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins. Cell Death Differ. 2012;19:1228–1238.
   PubMed Web of Science ®Google Scholar
• Rossin F, D’Eletto M, Macdonald D, et al. TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy. Amino Acids. 2012;42:1793–1802.
   PubMed Web of Science ®Google Scholar
• Rossin F, D’Eletto M, Farrace MG, et al. Transglutaminase type 2: a multifunctional protein chaperone? Mol Cell Oncol. 2014;1:e968506.
   PubMedGoogle Scholar
• Eckert RL, Kaartinen MT, Nurminskaya M, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014;94:383–417.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Pietrocola F, Levine B, et al. Metabolic control of autophagy. Cell. 2014;159:1263–1276.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280–293.
   PubMed Web of Science ®Google Scholar
• Katsuragi Y, IchimuraY KM. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. Febs J. 2015;282:4672–4678.
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009;137:1001–1004.
   PubMed Web of Science ®Google Scholar
• De Stefano D, Villella VR, Esposito S, et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 2014;10:2053–2074.
   PubMed Web of Science ®Google Scholar
• Cozza G, Pinna LA, Moro S. Kinase CK2 inhibition: an update. Curr Med Chem. 2013;20:671–693.
   PubMed Web of Science ®Google Scholar
• Luz S, Kongsuphol P, Mendes AI, et al. Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity. Mol Cell Biol. 2011;31:4392–4404.
   PubMed Web of Science ®Google Scholar
• Pagano MA, Marin O, Cozza G, et al. Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2. Biochem J. 2010;426:19–29.
   PubMed Web of Science ®Google Scholar
• Venerando A, Franchin C, Cant N, et al. Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation. PLoS One. 2013;8:e74232.
   PubMed Web of Science ®Google Scholar
• Venerando A, Ruzzene M, Pinna LA. Casein kinase: the triple meaning of a misnomer. Biochem J. 2014;460:141–156.
   PubMed Web of Science ®Google Scholar
• Da Silva VA, Zurbrügg RP, Lavanchy P, et al. Long-term treatment of infantile nephropathic cystinosis with cysteamine. N Engl J Med. 1985;313:1460–1463.
   PubMed Web of Science ®Google Scholar
• Medic G, Van Der Weijden M, Karabis A, et al. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis. Curr Med Res Opin. 2017;33:2065–2076.
   PubMed Web of Science ®Google Scholar
• Mou H, Brazauskas K, Rajagopal J. Personalized medicine for cystic fibrosis: establishing human model systems. Pediatr Pulmonol. 2015;50(S40):S14–23.
   PubMedGoogle Scholar
• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265.
   PubMed Web of Science ®Google Scholar
• Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013;340:1190–1194.
   PubMed Web of Science ®Google Scholar
• Dekkers JF, Wiegerinck CL, De Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19:939–945.
   PubMed Web of Science ®Google Scholar
• Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, et al. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. 2016;48:451–458.
   PubMed Web of Science ®Google Scholar
• Ikpa PT, Bijvelds MJ, De Jonge HR. Cystic fibrosis: toward personalized therapies. Int J Biochem Cell Biol. 2014;52:192–200.
   PubMed Web of Science ®Google Scholar
• Beekman JM, Sermet-Gaudelus I, De Boeck K, et al. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: report on the pre-conference meeting to the 11th ECFS basic science conference, Malta, 26-29 March 2014. J Cyst Fibros. 2014;13:363–372.
   PubMed Web of Science ®Google Scholar
• Awatade NT, Uliyakina I, Farinha CM, et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine. 2014;2:147–153.
   PubMed Web of Science ®Google Scholar
• Tosoni K, Cassidy D, Kerr B, et al. Using drugs to probe the variability of trans-epithelial airway resistance. PLoS ONE. 2016;11:e0149550.
   PubMed Web of Science ®Google Scholar
• Tosco A, De Gregorio F, Esposito S, et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ. 2016;23:1380–1393.
   PubMed Web of Science ®Google Scholar
• Ettorre M, Verzè G, Caldrer S, et al. Electrophysiological evaluation of cystic fibrosis conductance transmembrane regulator (CFTR) expression in human monocytes. Biochim Biophys Acta. 2014;1840:3088–3095.
   PubMed Web of Science ®Google Scholar
• Lavelle GM, White MM, Browne N, et al. Animal models of cystic fibrosis pathology: phenotypic parallels and divergences. Biomed Res Int. 2016;1–14. doi:10.1155/2016/5258727.
   Web of Science ®Google Scholar
• Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros. 2011;10:SS152–71.
   Web of Science ®Google Scholar
• Jain KK, ed. Textbook of Personalised Medicine. New York: Springer; 2009.
   Google Scholar
• Jain KK. Personalized medicine. Curr Opin Mol Ther. 2002;4:548–558.
   PubMedGoogle Scholar
• Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–611.
   PubMed Web of Science ®Google Scholar
• Corvol H, Thompson KE, Tabary O, et al. Translating the genetics of cystic fibrosis to personalized medicine. Transl Res. 2016;168:40–49.
   PubMed Web of Science ®Google Scholar
• Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2007;175:1036–1043.
   PubMed Web of Science ®Google Scholar
• The future of personalized medicine. CFF foundation available at www.cff.org/CF-Community-Blog/Posts/2015/The-Future-of-Personalized-Medicine/[2018 Feb 20]
   Google Scholar
• De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J. 2013;41:203–216.
   PubMed Web of Science ®Google Scholar